Skip to main content
. 2025 Feb 7;15:4593. doi: 10.1038/s41598-024-81704-4

Table 2.

Objective response to dacomitinib.

Treatment response Number of patients (%)
No. of cycles, median (range) 13 (2–24)
Complete response 1 (0.7%)
Partial response 128 (83.7%)
Stable disease 11 (7.2%)
Progressive disease 6 (3.9%)
Unknown 7 (4.6%)
Overall objective response rate 129 (84.3%)
Overall disease control rate 140 (91.5%)
Proportion overall PFS at 12 months 48.4%

PFS, progression-free survival.